Skip to content
Search

Latest Stories

MHRA recalls Beconase Aqueous Nasal Spray, Gliclazide 40 mg tablets

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 3 FMD medicines recall for Beconase Aqueous Nasal Spray and a class 2 pharmacy level recall for Gliclazide 40 mg Tablets.

Glaxo Wellcome UK Ltd T/A GSK is recalling the Beconase Aqueous Nasal Spray with batch number K84X, due to an issue related to error in the decommissioning.


This is the first falsified medicine directive (FMD) recall since July 2019.

“Upon decommissioning at the pharmacy and when scanning the serialised 2D code, the status of packs may report as ‘DESTROYED’,” the MHRA statement read.

Batch NumberExpiry DatePack SizeFirst Distributed
K84X09-2021106-Jan-2020

Accord UK is recalling all unexpired stock of Gliclazide 40 mg Tablets in Northstar Livery with batch number GU50 from pharmacies and wholesalers as a precautionary measure due to out of specification results for dissolution, obtained during routine stability testing.

Batch NumberExpiry DatePack SizeFirst Distributed
GU50Dec 20202824/05/2019

Pharmacists are asked to stop supplying both products immediately, quarantine remaining stock and return it to the supplier using the approved process.

The government agency also issued a class 4 pharmacy level caution in use for 13 batches of Atrolak (Quetiapine) prolonged release tablets by Accord, as the Patient Information Leaflet (PIL) within the packs are missing the side effects identified from post-marketing experience.

Pharmacists are adviced to ensure that patients are of any missing information and issue the current PILs with special warnings and precautions while dispensing the product.

Atrolak XL 50mg prolonged release tablets PL 20075/0213

Batch NumberExpiry DatePack SizeFirst Distributed
32272905/20216019 December 2019
Y0645510/20216003 September 2019

Atrolak XL 150mg prolonged release tablets PL 20075/0446

Batch NumberExpiry DatePack SizeFirst Distributed
Y0477110/20216006 November 2019
Y0478810/20216027 September 2019
Y0237405/20216007 August 2019

Atrolak XL 200mg prolonged release tablets PL 20075/0214

Batch NumberExpiry DatePack SizeFirst Distributed
X1765302/20216024 November 2019
Y0671008/20216018 November 2019

Atrolak XL 300mg prolonged release tablets PL 20075/0215

Batch NumberExpiry DatePack SizeFirst Distributed
Y0690909/20216004 October 2019
X2160205/20216007 April 2019
X1964903/20216003 July 2019
X1986603/20216011 June 2019

Atrolak XL 400mg prolonged release tablets PL 20075/0216

Batch NumberExpiry DatePack SizeFirst Distributed
X2182505/20216010 October 2019
X1876503/20216005 July 2019

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less